Pilocarpine has been used in the treatment of xerostomia; however, it is still uncertain whether it has a preventive effect on radiation-induced xerostomia. Our systematic review and meta-analysis demonstrated that concomitant administration of pilocarpine during radiation could increase unstimulated salivary flow rate and reduce clinician-rated xerostomia grade. It may also relieve patients' xerostomia at 6 months, and possibly at Purpose: To evaluate the efficacy of concomitant administration of pilocarpine on radiation-induced xerostomia in patients with head and neck cancers. Methods and Materials: The PubMed, Web of Science, Cochrane Library, and ClinicalTrials were searched to identify randomized, controlled trials studying the effect of concomitant administration of pilocarpine for radiation-induced xerostomia. Included trials were systematically reviewed, and quantifiable outcomes were pooled for metaanalysis. Outcomes of interest included salivary flow, clinician-rated xerostomia grade, patient-reported xerostomia scoring, quality of life, and adverse effects. Results: Six prospective, randomized, controlled trials in 8 articles were included in this systematic review. The total number of patients was 369 in the pilocarpine group and 367 in the control group. Concomitant administration of pilocarpine during radiation could increase the unstimulated salivary flow rate in a period of 3-6 months after treatment, and also reduce the clinician-rated xerostomia grade. Patient-reported xerostomia was not significantly impacted by pilocarpine in the initial 3 months but was superior at 6 month. No significant difference of stimulated salivary flow rate could be confirmed between the 2 arms. Adverse effects of pilocarpine were mild and tolerable. Conclusions: The concomitant administration of pilocarpine during radiation increases unstimulated salivary flow rate and reduces clinician-rated xerostomia grade
Introduction
Radiation therapy plays an important role in the multidisciplinary therapy of head and neck cancer, either as an adjunctive method or as the main treatment regimen. Among the acute and chronic side effects of radiation therapy, xerostomia is one of the most common complaints. Xerostomia is the subjective dryness of mouth, which may be associated with reduced salivary flow or changes in the composition of saliva (1, 2) . Individuals with xerostomia often complain of difficulties in speech and swallowing, impairment of taste, and deterioration of dental hygiene, greatly impairing patients' quality of life (QoL) (3) .
Some treatment options have been put forward to relieve radiation-induced xerostomia, including salivary substitutes and sialagogic agents (4) . Pilocarpine, a cholinergic agonist, stimulates saliva production and has been approved by the US Food and Drug Administration for the treatment of xerostomia. Preventive regimens are more promising, including submandibular gland transfer before radiation therapy, and parotid gland sparing techniques with 3-dimensional conformal or intensity modulated radiation therapy (IMRT) (5, 6) . However, only selected candidates are suitable for submandibular gland transfer. Studies have confirmed the significant role of IMRT in preventing xerostomia and maintaining normal oral functions (7) (8) (9) (10) (11) . Even with IMRT, however, the salivary glands may still overlap the planning target volume partially, resulting in some degree of salivary gland impairment and xerostomia (8, 12, 13 ).
An early clinical trial revealed that the concomitant administration of pilocarpine during radiation therapy was effective in preventing radiation-induced xerostomia in patients with head and neck cancers (14) . However, its exact efficacy is under investigation, and to date, no reported trial has been convincing enough to validate the efficacy of pilocarpine for the prevention of xerostomia. Compelling evidence is needed before concomitant pilocarpine can be recommended for routine use. Therefore, we aimed to conduct a systematic review and meta-analysis to evaluate the efficacy of concomitant administration of pilocarpine on radiation-induced xerostomia in patients with head and neck cancers.
Methods and Materials

Search strategy
We performed a comprehensive search in PubMed, Web of Science, Cochrane Library, and ClinicalTrials for relevant articles using different combinations of the following key words: "pilocarpine" or "salagen" and "radiation" or "radiotherapy" and "xerostomia" or "dry mouth" or "hyposalivation." All articles published up to September 1, 2014 were reviewed in the initial stage, without any other limitations on the publication type and language. We also hand-searched the reference lists of eligible studies and relevant conference abstracts. This process was repeated until no additional studies were found.
Selection criteria
Two authors independently reviewed and selected articles according to the following inclusion criteria: (1) Included studies should be randomized controlled trials. (2) Eligible patients were diagnosed with head and neck cancers, and underwent radiation therapy as primary or adjuvant therapy. 
Data extraction
Two authors independently reviewed the included articles and extracted data using a pre-established form, covering information about author, publication year, study design, country, sample size, tumor sites, exposed volume of salivary glands, intervention regimen, major endpoints, and duration of observation
Q3
. The completed forms were checked by a third author. Any inconsistency was resolved through discussion and consensus.
Assessment of risk of bias in included studies
The Cochrane Collaboration's tool (Cochrane Handbook version 5.1.0) for assessing risk of bias in randomized trials was adopted in this systematic review (15) . Two authors independently evaluated the risk of bias of included trials in 6 domains. We also contacted corresponding authors for further clarity of randomization, concealment, blinding method, and incomplete outcome data. If available information was insufficient to eliminate a bias, we would define it as "unclear risk" rather than "low risk."
Data analysis
Outcome variables were extracted for meta-analysis. For salivary flow rates, clinician-rated xerostomia grades, and patient-reported xerostomia scores, we calculated mean differences (MDs) with 95% confidence intervals (CIs) between groups during and after the course of radiation therapy (months). Mean differences were based on the fixed-effect model, because the estimate of between-study variance is poor when the number of studies is small (16). The fixed-effect meta-analysis provided the best pooled intervention effect estimate (17 
Results
Selection of trials
Of 495 reports initially identified ( Fig. 1 ), 471 were excluded by title and abstract. The remaining 24 reports were screened at full-text level. Relevant references were manually searched, and 2 additional reports were added. According to the predefined inclusion and exclusion criteria, 8 reports of 6 clinical trials were included (18-26) ( Table 1 ).
Description of the included studies and data analysis
All 6 trials in 8 articles were prospective trials. The trial by Fisher et al (19) Q5 was conducted in multiple centers in the United States, and the trial by Burlage et al (18) was conducted in 2 medical centers in the Netherlands, whereas the other included trials were single-centered.
The total number of patients was 369 in the pilocarpine group, and 367 in the control group. The mean age of patients was approximately 60 years in 5 trials (18-20, 22-26)
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. However, in the trial by Haddad et al (21) , the mean age of patients was 43 years, possibly owing to its different composition of tumors; most (76.9%) were nasopharyngeal carcinomas. The subtypes of tumors were reported according to their sites in every trial. The oropharynx, the oral cavity, and the larynx were the most commonly involved tumor sites, respectively accounting for 33.6%, 20.3%, and 19.5% (18) (19) (20) (21) (23) (24) (25) (26) . More than 50% of the bilateral parotid glands received a dose of 50 Gy in most of the trials. An exception was the trial by Burlage et al (18) : to study the influence of different exposed volumes of parotid glands, they recruited patients with a range of parotid volumes and divided them into 3 groups, which had an irradiated volume of parotid gland of 25%-45%, 46%-75%, and >75%, respectively.
A dose of 5 mg pilocarpine per administration was consistent in all the studies. Patients were instructed to take pilocarpine either 3 times daily, or 4 times. Patients took pilocarpine during radiation therapy and continued for different periods ranging from 2 weeks to 3 months. The period of follow-up varied from 5 weeks to 1 year after treatment (20, 22) .
Studied endpoints included objective, clinician-rated, and patient-reported indicators evaluating the alleviation of radiation-induced xerostomia. Objective data could be the salivary flow rate calculated as mL/min, including stimulated and unstimulated salivary flow rates. Clinician-rated grades of xerostomia according to the known scales were reviewed, such as the Late Effects of Normal Tissues Subjective, Objective, Management, and Analytic (LENT SOMA) scale, and the Radiation Therapy Oncology Group Acute Xerostomia Toxicity scale (27) (28) (29) . Patient-reported xerostomia was measured using a visual analogue scale or Likert scale when responding to xerostomia-related Volume -Number -2015 Pilocarpine prevents xerostomia 3   245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306   307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368 questions, such as the 1-item questionnaire by Gornitsky in 2004, the 6-item questionnaire by Johnson in 1993, and the 12-item questionnaire by Burlage in 2008 (20, 30-32) . Because these questionnaires all focused on xerostomia and the aspects evaluated were similar, we extracted mean patient-reported scores, representing the overall xerostomia, at each time point. The scores were standardized on a 0-100 scale for final synthesis (32) . The impact of xerostomia on patients' QoL was evaluated through validated questionnaires, such as the McMaster University Head and Neck Questionnaire, and the University of Washington-Quality of Life Questionnaire. Finally, adverse effects of pilocarpine were qualitatively assessed by reviewing records in the included clinical trials. Studies containing one or more of the above endpoints were included and thoroughly reviewed.
Risk of bias in included studies
The 6 included studies were all prospective, randomized clinical trials. It was difficult to gain information regarding allocation concealment and eliminate the risk of selection bias. In the trial by Fisher et al (19) , eligible patients from multiple centers were registered to a treatment arm by Radiation Therapy Oncology Group headquarters, and patient factors were balanced by the headquarters other than by institutions. Most of the other studies, though, neglected to describe their methods of performing allocation. Considering performance bias, in the trial by Nyarady et al (23) , the control group received neither pilocarpine nor placebo, so double-blinding was violated. Unclear information about the number of early dropouts was considered to be bias-producing. Intention-to-treat analysis was regarded as an ideal statistical method in such circumstances. In the study by Gornitsky et al (20) , a missing data replacement technique was used, using mean values from corresponding groups. In the study by Fisher et al (19) the schedule for data collection of the University of Washington Quality of Life Questionnaire at the completion of radiation therapy was not carried out (Fig. 2) .
Efficacy and safety of concomitant pilocarpine for radiation-induced xerostomia Salivary flow rate Three included studies measured unstimulated salivary flow rate. Their data at each time point were synthesized to calculate the MDs between groups. At baseline the unstimulated salivary flow rates were similar between the pilocarpine and control groups (MD À0.02 mL/min; 95% CI -0.13, 0.09; PZ.68). During radiation therapy the concomitant administration of pilocarpine increased the amount of unstimulated saliva per minute. Immediately after radiation therapy the unstimulated salivary flow rate of the pilocarpine group was significantly increased (MD 0.28 mL/min; 95% CI 0.18, 0.37; P<.00001). The advantageous effect of pilocarpine continued for 3 months after radiation therapy; however, the increased rates declined over time. At 5-6 weeks, the increase of unstimulated salivary flow rate was 0.15 mL/min (95% CI 0.07, 0.24; PZ.0005), and at 3 months the increased rate was 0.10 mL/ min (95% CI 0.00, 0.20; PZ.04). By 6 months after radiation therapy the difference between groups was insignificant (MD 0.10 mL/min; 95% CI À0.02, 0.22; PZ.09) (Fig. 3) .
A significant decrease in stimulated salivary flow rate after radiation therapy was observed in 2 trials. However, no significant difference was detected between arms (18, 20, 25).
Clinician-rated scoring of xerostomia Two included studies measured the xerostomia grade using the LENT SOMA scale. Available data were synthesized at 6 months. The severity of xerostomia was less in the pilocarpine group (MD À0.41 points; 95% CI À0.65, À0.17; PZ.0008) (Fig. 4) .
Patient-reported scoring of xerostomia
Four included studies provided patient-reported xerostomia scores. Xerostomia was complained of during radiation therapy and persisted in the following 12 months. At baseline, xerostomia scores were similar between the pilocarpine and control groups (MD À0.46; 95% CI À4.76, 3.84; PZ.83). After radiation therapy, patients in the pilocarpine group did feel a little better than those in the control group (MD À9.40; 95% CI À17.96, À0.83; PZ.03). However, at 1-3 months after radiation therapy, patients' scorings of xerostomia were not significantly different. Thereafter at 6 months, the xerostomia scores in the pilocarpine group were better than those in the control group ( (Fig. 5) .
Quality of life
Two trials adopted validated questionnaires to assess QoL. XXXX Q8 et al used the McMaster University Head and Neck questionnaire, revealing no difference between the pilocarpine and the placebo groups during or after radiation therapy. The QoL declined significantly during radiation therapy but gradually returned to the baseline score by 6 months after treatment. The patient-reported xerostomia, in contrast with the QoL, worsened and persisted in both arms (24, 26) . Fisher et al used the University of Washington Head and Neck Symptom Scale questionnaire in their trial. Even though the unstimulated saliva increased in the pilocarpine group, no improvement in QoL during the follow-up 6 months was reported (19, 25) .
Adverse effects of pilocarpine Several included articles reported adverse effects of pilocarpine, including nausea, lacrimation, sweating, rhinitis, mild headache, and urinary frequency (21, 23, 26) . The observed adverse effects were usually mild and tolerable. Meta-analysis was not performed because included studies failed to report quantifiable outcome measures. On the basis of the original report from the largest trial, no statistical difference was reported between the pilocarpine group and the placebo group (25) . Only 1 patient receiving pilocarpine discontinued the medication because of excessive sweating (18).
Discussion
The efficacy of pilocarpine on the treatment of radiationinduced xerostomia has been studied since the 1990s (31) . The morbidity of radiation-induced xerostomia is better avoided than treated (21) . Thus, the preventive effect of Volume -Number -2015 Pilocarpine prevents xerostomia 5   493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554   555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609  610  611  612  613  614  615  616 pilocarpine deserved attention through high-quality randomized, controlled trials. We searched online databases and identified 6 randomized, controlled trials in a metaanalysis, addressing this question. The results showed that concomitant administration of pilocarpine during radiation could increase the unstimulated salivary flow rate over a period of 3-6 months after treatment, alleviate the severity of clinician-rated xerostomia grade up to 6 months after treatment, and possibly relieve patient-reported xerostomia during the time frame of 6-12 months after treatment.
Our meta-analysis demonstrated that preventive pilocarpine could increase the unstimulated salivary flow rate, but the advantageous effect continued for only a period of 3-6 months. In the first 6 months, concomitant pilocarpine exhibited a favorable effect, but over time the relative increased unstimulated salivary flow rate kept descending. This phenomenon could be due to different mechanisms of salivary gland damage induced by radiation in different time phases. In the early phase after radiation, the main mechanism of xerostomia is attributable to plasma membrane damage, which could be prevented by pilocarpine or other specific receptor agonists (33) . An in vivo study by Burlage et al (34) discovered that pilocarpine could increase proliferation of undamaged cells in the early phase when there was a sufficient number of remaining progenitor cells. In the late phase (approximately 120 days later), salivary flow rate further deteriorated, because of acinar cell apoptosis and the damaged extracellular environment (35) . Thus the concomitant application of pilocarpine was hypothesized to be effective only in the early phase of radiation-induced xerostomia. The protective effect may also have accounted for the decreased clinician-rated xerostomia grade at 6 months.
Although the unstimulated saliva flow improved in the pilocarpine group, pilocarpine had no effect on stimulated salivary flow rate. It was suggested that the parotid glands, which produce stimulated saliva, might be more vulnerable to radiation (36) , and the recoverability of the parotid glands after radiation might be weaker than the mucous salivary glands. However, the assumption was rejected by subsequent studies (37, 38) , which showed that the functional loss was quite comparable between the parotid and submandibular glands (37) . The inconsistent response to pilocarpine between the unstimulated and stimulated saliva might result from the sialagogic effect of pilocarpine. The web 4C=FPO Fig. 5 . Subjective xerostomia scores during and after course of radiation therapy. Depicts mean differences between the pilocarpine group and the control group. Abbreviation: CI Z confidence interval.
daily administration of pilocarpine was presumed to keep the salivary glands in the stimulated condition. When secreting at a maximum rate, no more saliva could be secreted even with another stimulus, hence the stimulated saliva showed no significant change. Our finding was similar to those from the study by Wasserman et al (39) , who observed a significant increase in unstimulated saliva production but found no difference in stimulated saliva flow in patients receiving the radioprotective agent of amifostine.
With respect to the patient-reported xerostomia, pilocarpine alleviated symptoms at 6 months, and possibly at 12 months (although only 1 study provided 12-month data). Considering the minimally important difference of 5-10% improvement required to prove the clinical value of pilocarpine, the patient-reported xerostomia at 6 months was of borderline significance (40) . The discrepancy between patient-reported xerostomia and unstimulated saliva might be attributed to the varied and uncontrolled radiation doses of the submandibular glands and minor salivary glands, which would affect mucin secretion and was a critical factor for the patient-reported xerostomia scores (11, (41) (42) (43) .
Two included trials found concomitant administration of pilocarpine during radiation therapy could not significantly improve QoL compared with the placebo group (19, 24) . One potential reason may be that the adopted QoL questionnaire did not adequately measure xerostomia (24, 44) . Fisher et al (19) explained that the ameliorated xerostomia was not perceived to be ideal, negatively affecting patients' self-appraisal of their status. Another possibility is that the radiation-induced mucositis produces similar dysfunctions as xerostomia, and thus reduces the QoL (19). Jellema et al (45) evaluated patients' xerostomia and QoL using the Radiation Therapy Oncology Group acute morbidity scoring criteria and the European Organization for Research and Treatment of Cancer QLC-C30. They found a significant impact of clinician-rated xerostomia on QoL, and the effect size increased over time even as the incidence of xerostomia decreased. The inconsistency in different studies indicates that the correlation between saliva flow, clinician-or patient-rated xerostomia, and QoL is complicated and should be further clarified in future studies.
The effect of pilocarpine on increasing unstimulated saliva needs to be highlighted even in the IMRT era. Intensity modulated radiation therapy is most useful in sparing the parotid glands (46) and can be combined with pilocarpine to obtain a complementary outcome. Even with IMRT, xerostomia is still a common side effect (13) . Patients with N2c lymph node disease will often have marginal sparing of bilateral parotid glands, and large tumors of base of tongue may preclude submandibular glands sparing. Such circumstances will cause unavoidable radiation-induced xerostomia, which underlines the role of pilocarpine. Furthermore, IMRT produces long-term relief of xerostomia (8) , whereas pilocarpine has more of a shortterm benefit. Therefore, the combination of pilocarpine and IMRT is promising in preventing xerostomia and warrants further investigation.
Certain limitations in this systematic review should be taken into account. First, the number of included studies is limited, which underlines the necessity to combine available evidence for clinical guidance. Relevant outcomes should be interpreted carefully, and further high-quality trials are proposed. Second, the long-term efficacy of pilocarpine has to be further investigated, because no study in our analysis tracked outcomes beyond 12 months. Last, the adopted patient-reported or clinician-rated instruments for grading xerostomia, or the QoL questionnaires, are diverse, bringing about difficulty in comparing studies. A guideline concerning the design and implementation of future clinical trials should be recommended.
Conclusions
The concomitant administration of pilocarpine during radiation can increase unstimulated salivary flow rate and reduce clinician-rated xerostomia grade after radiation. It may also relieve patients' xerostomia at 6 months, and possibly at 12 months. However, it has no effects on stimulated salivary flow rate. More high-quality trials are needed, with standardized outcome measures including the normalized measurement of salivary flow, clinician-rated xerostomia grade, patient-reported xerostomia, and a specialized QoL questionnaire. 927  928  929  930  931  932  933  934  935  936  937  938  939  940  941  942  943  944  945  946  947  948  949  950  951  952  953  954  955  956  957  958  959  960  961  962  963  964  965  966  967  968  969  970  971  972  973  974  975  976  977  978  979  980  981  982  983  984  985  986  987  988 
